Farletuzumab ecteribulin
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
Product Specifications
CAS Number
2407465-18-1
Product Name Alternative
MORAb-202
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/farletuzumab-ecteribulin.html
Purity
99.40
Solubility
H2O
Smiles
[Farletuzumabecteribulin]
Molecular Weight
149000 (average)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
RBM26, NT (RBM26, C13orf10, RNA-binding protein 26, CTCL tumor antigen se70-2, RNA-binding motif protein 26) (MaxLight 750)
RBM26, NT (RBM26, C13orf10, RNA-binding protein 26, CTCL tumor antigen se70-2, RNA-binding motif protein 26) (MaxLight 750)
C12orf37 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
